Literature DB >> 21862646

Simple estimation of clinically relevant lesion volumes using spectral domain-optical coherence tomography in neovascular age-related macular degeneration.

Florian M Heussen1, Yanling Ouyang, Srinivas R Sadda, Alexander C Walsh.   

Abstract

PURPOSE: To evaluate simple methods of estimating the volume of clinically relevant features in neovascular age-related macular degeneration (NVAMD) using spectral domain-optical coherence tomography (SD-OCT).
METHODS: Using a database of NVAMD cases imaged with macular cube (512 A-scans × 128 B-scans) SD-OCT scans, the authors retrospectively selected visits where cystoid macular edema (CME), subretinal fluid (SRF), or pigment epithelial detachments (PEDs) were evident. Patients with single visits were analyzed in the cross-sectional analysis (CSA) and those with a baseline visit and three or more follow-up visits in the longitudinal analysis (LA). The volume of each feature was measured by manual grading using validated grading software. Simplified measurements for each feature included: number of B-scans or A-scans involved and maximum height. Automated measurements of total macular volume and foveal central subfield were also collected from each machine. Correlations were performed between the volumes measured with 3D-OCTOR, automated measurements, and the simplified measures.
RESULTS: Forty-five visits for 25 patients were included in this study: 26 cube scans from 26 eyes of 25 patients in the CSA and 24 scans from 5 eyes of 5 patients in the LA. The simplified measures that correlated best with manual grading in the CSA group were maximum lesion height for CME (r² value = 0.96) and B-scan count for SRF and PED volume (r² values of 0.88 and 0.70). In the LA group, intervisit differences were correlated. Change in B-scan count correlated well with change in SRF volume (r² = 0.97), whereas change in maximum height correlated with change in CME and PED volume (r² = 0.98 and 0.43, respectively).
CONCLUSIONS: These data suggest that simplified estimators of some NVAMD lesion volumes exist and are accessible by clinicians without the need for specialized software or time-consuming manual segmentation. These simple approaches could enhance quantitative disease monitoring strategies in clinical trials and clinical practice.

Entities:  

Mesh:

Year:  2011        PMID: 21862646      PMCID: PMC3183988          DOI: 10.1167/iovs.11-8023

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  16 in total

1.  Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.

Authors:  Srinivas R Sadda; Glenn Stoller; David S Boyer; Barbara A Blodi; Howard Shapiro; Tsontcho Ianchulev
Journal:  Retina       Date:  2010-10       Impact factor: 4.256

2.  Error correction and quantitative subanalysis of optical coherence tomography data using computer-assisted grading.

Authors:  Srinivas R Sadda; Sandra Joeres; Ziqiang Wu; Paul Updike; Peggy Romano; Allyson T Collins; Alexander C Walsh
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

3.  Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration.

Authors:  Praveen J Patel; Fred K Chen; Felicia Ikeji; Wen Xing; Catey Bunce; Lyndon Da Cruz; Adnan Tufail
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03       Impact factor: 4.799

4.  Quality of the threshold algorithm in age-related macular degeneration: Stratus versus Cirrus OCT.

Authors:  Ilse Krebs; Christiane Falkner-Radler; Stefan Hagen; Paulina Haas; Werner Brannath; Shilla Lie; Siamak Ansari-Shahrezaei; Susanne Binder
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-21       Impact factor: 4.799

5.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Authors:  Anne E Fung; Geeta A Lalwani; Philip J Rosenfeld; Sander R Dubovy; Stephan Michels; William J Feuer; Carmen A Puliafito; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2007-04       Impact factor: 5.258

7.  Errors in retinal thickness measurements obtained by optical coherence tomography.

Authors:  Srinivas R Sadda; Ziqiang Wu; Alexander C Walsh; Len Richine; Jessica Dougall; Richard Cortez; Laurie D LaBree
Journal:  Ophthalmology       Date:  2006-01-10       Impact factor: 12.079

8.  Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration.

Authors:  Sandra Joeres; Jerry W Tsong; Paul G Updike; Allyson T Collins; Laurie Dustin; Alexander C Walsh; Peggy W Romano; SriniVas R Sadda
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

9.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

Authors:  Carl D Regillo; David M Brown; Prema Abraham; Huibin Yue; Tsontcho Ianchulev; Susan Schneider; Naveed Shams
Journal:  Am J Ophthalmol       Date:  2008-02       Impact factor: 5.258

10.  Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Authors:  Peter K Kaiser; Barbara A Blodi; Howard Shapiro; Nisha R Acharya
Journal:  Ophthalmology       Date:  2007-07-12       Impact factor: 12.079

View more
  6 in total

1.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  Optical coherence tomography characteristics of responses to intravitreal bevacizumab in idiopathic choroidal neovascularization.

Authors:  Syed Nasir Ali Shah; Qian-Yan Kang; Xiao-Juan Fan; Yue-Ming Sun
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

3.  Two-year outcomes of episcleral brachytherapy adjunct to anti-VEGF therapy for treatment-resistant nAMD.

Authors:  Jay Chhablani; Rama Jager; Joshua Ong; Ryan Lohrenz; Russell J Hamilton; Baldassare Stea; Mary Drew; Gregg Kokame
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-17       Impact factor: 3.117

4.  Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis.

Authors:  SriniVas Sadda; Nancy M Holekamp; David Sarraf; Adel Ebraheem; Wenying Fan; Lauren Hill; Steve Blotner; Galin Spicer; Shamika Gune
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-10       Impact factor: 3.117

5.  Evaluation of cystoid change phenotypes in ocular toxoplasmosis using optical coherence tomography.

Authors:  Yanling Ouyang; Uwe Pleyer; Qing Shao; Pearse A Keane; Nicole Stübiger; Antonia M Joussen; Srinivas R Sadda; Florian M Heussen
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

6.  Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series.

Authors:  Geraldine R Slean; Kornwipa Hemarat; Rahul N Khurana; Jay M Stewart
Journal:  Int J Retina Vitreous       Date:  2016-01-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.